Compare PRG & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRG | URGN |
|---|---|---|
| Founded | 2020 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2020 | 2016 |
| Metric | PRG | URGN |
|---|---|---|
| Price | $34.14 | $29.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $50.00 | $29.29 |
| AVG Volume (30 Days) | 429.7K | ★ 931.0K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $2,409,223,000.00 | $1,128,000.00 |
| Revenue This Year | $23.77 | $129.09 |
| Revenue Next Year | $7.91 | $70.96 |
| P/E Ratio | $37.80 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.80 | $3.42 |
| 52 Week High | $41.14 | $32.37 |
| Indicator | PRG | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.45 | 66.69 |
| Support Level | $32.07 | $17.86 |
| Resistance Level | $34.43 | $30.00 |
| Average True Range (ATR) | 1.60 | 1.97 |
| MACD | -0.13 | 0.51 |
| Stochastic Oscillator | 65.20 | 71.93 |
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.